Karnataka demands price controls after FSDA finds drugs marked up 52.6 times cost
GS2Polity · Governance · IR· Health policy & public health· Prelims + Mains·
Pharmaceutical regulation and public health governance: a GS2 case study on market transparency and medicine affordability.
Why in news
Karnataka Health Minister U.T. Khader wrote to the Union Ministry of Health and NPPA demanding expanded price controls after the FSDA identified drugs with markups as high as 52.6 times the landing cost.
Background
The Food Safety and Drug Administration (FSDA) identified 253 drugs with extreme markups, notably Cytax 100 mg which had a landing cost of ₹342 but an MRP of ₹3,836. The state government initiated a verification drive on September 25-26 to address these discrepancies.
Facts for Prelims
- FactCytax 100 mg: Identified drug with a landing cost of ₹342 and an MRP of ₹3,836.
- FactFSDA findings: 253 drugs were found with markups up to 52.6 times the cost.
Prelims practice question
With reference to pharmaceutical price regulation in Karnataka, consider the following statements:
- The markup on identified drugs was as high as 52.6 times the landing cost.
- The landing cost of Cytax 100 mg was identified as ₹3,836.
- The FSDA identified 253 drugs with extreme markups.
Which of the statements given above is/are correct?
- (a)1 only
- (b)3 only
- (c)1 and 3 only
- (d)2 and 3 only
Show answer
Answer: (c) 1 and 3 only — Statements 1 and 3 are correct. Statement 2 is incorrect: The landing cost of Cytax 100 mg was ₹342, while the MRP was ₹3,836.
For Mains
Q. Critically analyze the challenges in regulating pharmaceutical price markups in India and suggest measures to ensure affordable access to essential medicines.
Dimensions to cover in your answer
- Regulatory arbitrage: Exploitation of price gaps between landing costs and MRP for non-essential drugs
- Transparency deficit: Lack of real-time tracking of supply chain markups between distributors and retailers
- Market distortion: High markups on specific drugs like Cytax 100 mg hindering universal healthcare access
Keywords: Price Control · Pharmaceutical Regulation · Market Transparency · Affordability · Public Health Governance
More Social Justice notes
- Kerala issues 10,000 title deeds for Attappady land to SC, ST and fishing communities · 8 October 2026
- Supreme Court directs Union government to form committee on legally enforceable pharmaceutical marketing code · 8 October 2026
- Finance Ministry mandates bank-wise data on SC beneficiaries for Mudra, Stand Up India schemes · 8 October 2026
- Madras High Court dismisses Kanzeon Trust appeal after it misrepresented Zen Buddhist activities · 8 October 2026
- Tamil Nadu amends Thaimaaman Thanga Mothiram Thittam to include children of out-of-state mothers · 8 October 2026
- Odisha forms Justice Pramath Patnaik-led commission to study SEBC representation before next year's polls · 8 October 2026
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.